Aribio to Hold Korean Clinical Experts Meeting on AR1001 Global Phase 3 Trial on August 22-23

Aribio announced on August 14 that it will hold a meeting of Korean clinical experts regarding the global Phase 3 clinical trial of its oral Alzheimer's treatment candidate, AR1001, from August 22 to 23.

This meeting is co-hosted by Aribio and Samjin Pharmaceutical. The principal investigators from all 26 major medical institutions in Korea participating in the AR1001 Phase 3 clinical trial will attend.

The event will feature in-depth discussions on the latest updates from the global Phase 3 clinical trial (Polaris-AD AR1001 Global PIII Trial), the current status and interim analysis of the clinical progress, and strategies for data quality management through to the scheduled completion of the trial in the first half of 2026. Researchers will also share their experiences and suggestions during an on-site discussion session.

The AR1001 global Phase 3 trial (Polaris-AD) targets patients with early-stage Alzheimer's disease. It is a double-blind, randomized, placebo-controlled study designed to evaluate safety and efficacy. Patient enrollment has been completed for 1,535 participants across 230 clinical centers in 13 countries worldwide, and more than 300 patients have already completed dosing. In Korea, the study is being conducted with 200 participants.

An Aribio representative stated, "This meeting is an important opportunity to share the achievements and strategies of the global Phase 3 clinical trial, and to enhance its quality by incorporating the experiences and opinions of the researchers." The representative added, "Through close collaboration with domestic researchers, we aim to successfully complete the AR1001 clinical trial and accelerate its global commercialization."

On August 5, Aribio announced that it had observed a positive trend, with cognitive and daily functioning maintained or improved in 41.6% of all patients enrolled in the trial. The company is currently pursuing a merger with Kosdaq-listed Solux. The merger date is scheduled for November 4.